Details of the Drug Combination

General Information of Drug Combination (ID: DCZDNXX)

• Drug Combination Name: Piperacetazine + PM1183
• Indication: Lymphoid neoplasm; Status: Investigative [1]
• Component Drugs:
  Piperacetazine (DMGQU0Y): Small molecular drug
  PM1183 (DMZZGWP): N.A.
• High-throughput Screening Result:
  Testing Cell Line: Mak
  Zero Interaction Potency (ZIP) Score: 6.406
  Bliss Independence Score: 10.963
  Loewe Additivity Score: 3.661
  LHighest Single Agent (HSA) Score: 3.035

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Piperacetazine

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[2]

Piperacetazine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[4]

Piperacetazine Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[5]

Indication(s) of PM1183

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.